Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses

Open Access

Peer-reviewed

Research Article

Jack T. Nguyen ,

* E-mail: jnguyen@adamaspharma.com

Affiliation Adamas Pharmaceuticals, Inc., Emeryville, California, United States of America
⨯
Donald F. Smee,

Affiliation Utah State University, Logan, Utah, United States of America
⨯
Dale L. Barnard,

Affiliation Utah State University, Logan, Utah, United States of America
⨯
Justin G. Julander,

Affiliation Utah State University, Logan, Utah, United States of America
⨯
Matthew Gross,

Affiliation Adamas Pharmaceuticals, Inc., Emeryville, California, United States of America
⨯
Menno D. de Jong,

Affiliation Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
⨯
Gregory T. Went

Affiliation Adamas Pharmaceuticals, Inc., Emeryville, California, United States of America
⨯

Reader Comments (0)

Antiviral therapy
Is the Subject Area "Antiviral therapy" applicable to this article?

Thanks for your feedback.
Influenza
Is the Subject Area "Influenza" applicable to this article?

Thanks for your feedback.
Weight loss
Is the Subject Area "Weight loss" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Influenza viruses
Is the Subject Area "Influenza viruses" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Body weight
Is the Subject Area "Body weight" applicable to this article?

Thanks for your feedback.
Antivirals
Is the Subject Area "Antivirals" applicable to this article?

Thanks for your feedback.